SUBOXONE combines a partial opioid agonist (buprenorphine) and an opioid antagonist (naloxone) in a 4:1 (buprenorphine: naloxone) ratio.
Buprenorphine (the primary active compound) reduces patients’ opioid cravings and withdrawal symptoms. In addition, buprenorphine may discourage patients’ use of nonprescribed opioids by binding to the mu receptor, thereby blocking other opioids’ effects.
The naloxone component in SUBOXONE is included to help discourage diversion and misuse. Naloxone has very limited bioavailability when administered sublingually, as intended. However, if SUBOXONE is crushed and injected, the naloxone will precipitate opioid withdrawal. In the absence of an opioid, the antagonist has no effect.
Effective Individualized Suboxone Treatment Program in the privacy and confidentiality of a Doctor’s Office!
Although short-term treatment may be an effective option for some people, the chance of relapsing can be higher. Physical dependence is only one part of opioid dependence and short-term treatments do not allow enough time to address the psychological and behavioral components of the disease, therefore patients have less time to learn the necessary skills to maintain an opioid-free lifestyle.